Braveheart Bio, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-07-15. It has amended it 1 time. It filed its final prospectus on 2026-08-06, at a public offering price of $18.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our common stock has been approved for listing on The Nasdaq Global Market (“Nasdaq”) under the symbol “BRVE”.From the 424B4 filed 2026-08-06
Shares offered
This is the initial public offering of shares of common stock of Braveheart Bio, Inc. We are offering 21,250,000 shares of our common stock.From the 424B4 filed 2026-08-06
Offering price
The initial public offering price per share is $18.00.From the 424B4 filed 2026-08-06
Use of proceeds
We currently intend to use the net proceeds we receive from this offering, together with our existing cash and cash equivalents, (i) to advance the development of BHB-1893 in patients with obstructive hypertrophic cardiomyopathy, including a Phase 3 clinical trial to evaluate the safety and efficacy of BHB-1893 through completion of such trial, (ii) to advance the development of BHB-1893 in patients with non-obstructive hypertrophic cardiomyopathy, including a Phase 3 clinical trial to evaluate the safety and efficacy of BHB-1893 in adults with symptomatic, non-obstructive hypertrophic cardiomyopathy, through the completion of such trial, (iii) to fund research and development personnel…From the 424B4 filed 2026-08-06
Revenue
Table of Contents than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year.From the S-1 filed 2026-07-15
Net loss or income
Our net losses were $14.3 million and $66.1 million for the three months ended March 31, 2026 and for the year ended December 31, 2025, respectively.From the S-1/A filed 2026-07-30
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2026-07-15 | Registration statement filed | S-1 |
| 2026-07-30 | Registration statement amended | S-1/A |
| 2026-08-06 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Braveheart Bio, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.